ReviewClinical pharmacokinetics2008
The enzymatic basis of drug-drug interactions with systemic triazole antifungals.
Review in Clinical pharmacokinetics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 135 citations in OpenAlex.
- Trial
- Serum 4β-hydroxycholesterol increases during fluconazole treatment.European journal of clinical pharmacology · 2021Trial
- Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.Antimicrobial agents and chemotherapy · 2016Trial
- S-ketamine concentrations are greatly increased by grapefruit juice.European journal of clinical pharmacology · 2012Trial
- Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Antimicrobial agents and chemotherapy · 2011Trial
- Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.British journal of clinical pharmacology · 2011Trial
- Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.Bone marrow transplantation · 2010Trial
- Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective.Journal of clinical medicine · 2025Review
- Invasive Trichoderma longibrachiatum breakthrough infection in a hematology patient.Medical mycology case reports · 2025Article
- Review of the novel antifungal drug olorofim (F901318).BMC infectious diseases · 2024Review
- Outcomes of Invasive Fungal Infections Treated with Isavuconazole: A Retrospective Review.Pathogens (Basel, Switzerland) · 2024Article
- On the Question of Zwitterionic Intermediates in the [3+2] Cycloaddition Reactions between Aryl Azides and Ethyl Propiolate.Molecules (Basel, Switzerland) · 2023Article
- Spinal Infections Caused byMaedica · 2023Article
- Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management.Drug safety · 2023Review
- Article
- Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction.PloS one · 2023Article
- Effects of antifungal drugs on the plasma concentrations and dosage of tacrolimus in kidney transplant patients.European journal of hospital pharmacy : science and practice · 2022Article
- Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.Pharmacology research & perspectives · 2022Article
- Skeletal Infections Caused byDiagnostics (Basel, Switzerland) · 2022Review
- Antidermatophytic activity of some newly synthesized arylhydrazonothiazoles conjugated with monoclonal antibody.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-drug interactions are a recurring problem in immunocompromised patients treated with triazole antifungals. While the introduction of new antifungals has expanded opportunities for lowering drug toxicity, virtually all antifungal regimens carry the risk of pharmacokinetic and pharmacodynamic interaction. This review presents the published data on molecular determinants (enzymes, transporters, orphan nuclear receptors) of systemic triazole pharmacokinetics in humans, including itraconazole, fluconazole, voriconazole and posaconazole. Systemic triazoles are inhibitors of cytochrome P450 (CYP) isozymes, such as CYP3A4, CYP2C9 and CYP2C19, to varying degrees. In addition, some are substrates and/or inhibitors of drug transporters such as multidrug resistance-1 gene product, P-glycoprotein, or breast cancer resistance protein. The interactions of triazole antifungals can be divided into the following categories: modifications of antifungal pharmacokinetics by other drugs, modifications of other drug pharmacokinetics by antifungals, and two-way interactions. These features are the basis of most interactions that occur during triazole therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.